Today's Date: April 11, 2021
Get Start to Train Your Own Service Dog Online with Service Dog Training School International - Certified Service Dog Training C   •   CGTN: From well-educated students to radicalized extremists in Xinjiang   •   Who’s Getting Vaccinated in the US?   •   Publix Pharmacy Now Offering COVID-19 Vaccination Appointments in North Carolina   •   Wolters Kluwer Podcast Sheds Light on Key Factors Impacting Effective Banking Compliance   •   The American Legion Calls POW/MIA Flag above White House "A Poignant Reminder"   •   genEquality’s First Inclusive Safety Mural Launches at Townsend Harris High School in Flushing, Queens   •   Charmin® Works to Protect, Grow and Restore Forests   •   Minister Schulte and Minister Hajdu announce the appointment of three new members to the National Seniors Council   •   Call for Programs Opens for 2021 Parliament of the World's Religions   •   BET Remembers Hip-Hop Icon DMX With Special Linear Programming Today Starting At 6PM/5C   •   ‘Coming Out for Love’ LGBTQ Reality Dating Show Headed for Romance, Fun, Happy Endings This Fall   •   The Drone Champions League puts female drone pilots in the global spotlight with the DCL Women's Cup   •   Winning Startups Receive $25,000 through Sunstone Innovation Challenge at CSULB   •   Barna and Gloo To Release New City-Specific Research Experience For Church Leaders   •   PG&E Contributes $500,000 to Restaurant Resilience Fund to Strengthen Businesses for the Long-Term   •   Humanitarian Leaders Jamie Aten and Kent Annan launch petition to encourage Evangelicals to get vaccinated against COVID-19   •   Pets play important role in easing children's loneliness and stress intensified by virtual schooling in lockdown   •   Molina Healthcare of California Partners with San Bernardino County for COVID-19 Vaccinations   •   Ather Sharif Awarded The Excellence in Entrepreneurial Leadership Award In Honor of Michael Ferro
Bookmark and Share

UN Study: It’s Time To Reassess Where We Stand With An HIV Vaccine

 

 

 

 

According to a recent United Nations study, HIV infection rates among high-risk groups such as gays, drug users and sex workers are on the rise around the world.

U.N. AIDS agency chief Michel Sidibe is saying the increase may be due to worsening discrimination against these groups in certain countries. In the U.S., despite laws that are more tolerant of homosexuality, more than half of all new HIV infections in 2009 occurred among gay men, which Sidibe called "shocking." In the U.S., Sidibe said, "it seems like we have come full circle," and not in a good way.

Contrary to what many perceive, HIV is not going away. These increases in HIV rates nationally and globally demand a renewed focus on how the international community can battle this pandemic.

Mark J. Newman, Ph.D., Vice President of Research and Development at GeoVax Labs, Inc., a biotechnology company focusing on developing vaccines to protect against or to treat diseases caused by human immunodeficiency virus (HIV), believes now is a better time than ever to begin reassessing the importance not only of a preventative vaccine to address the high-risk population, but also of a therapeutic vaccine to keep those with active HIV from progressing to full-blown AIDS.

Dr. Newman is available to discuss: 
Can vaccines curb the rising numbers of HIV cases? 
What are the challenges of bringing a vaccine for HIV to market? 
What has stalled progress and what does the future hold? 
How is science harnessing the power of the immune system to fight HIV?

About Dr. Mark J. Newman 
In a career spanning 30 years, Dr. Newman, was Vice President, Research and Development for PaxVax, Inc., prior to joining GeoVax. At PaxVax, he led research and preclinical development of Adenovirus vectored vaccine candidates. During his professional life he has worked on the development of HIV, influenza and cancer vaccines and led active programs on adjuvant and vaccine delivery technologies. Over the past 20 years he has served in various senior management roles within the biotechnology field with a focus on HIV/AIDS vaccines. He holds B.Sc. and M.Sc. degrees from Ohio State University. He also holds a Ph.D. in Immunology from the John Curtin School of Medical Research at the Australian National University. In his scientific career he has successfully secured peer-reviewed grants and contracts, is an inventor on seven issued patents, and an author of more than 100 peer-reviewed scientific papers. He has provided extensive service to the field of HIV/AIDS vaccines by serving on extramural panels for the review of US NIH-sponsored HIV/AIDS and vaccine research programs.

About GeoVax Labs, Inc. 
The ongoing research and development programs at GeoVax are focused on the clinical development of its DNA and MVA vaccines for the prevention and/or treatment of HIV/AIDS. It is developing two clinical pathways for its vaccine candidates, as a preventative vaccine to prevent development of AIDS in healthy individuals who are exposed to the HIV virus and as a therapeutic vaccine to prevent development of AIDS in those individuals who have already been infected with the HIV virus.

For further information about GeoVax Labs, Inc. please visit:www.geovax.com

 
Source: GeoVax Labs



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News